Potential new therapy could reduce dangerous post-heart-attack inflammation

June 08, 2016

A new study led by investigators at Massachusetts General Hospital (MGH) has identified a mechanism behind the surge in cardiovascular inflammation that takes place after a heart attack. Working with collaborators from the Massachusetts Institute of Technology (MIT), the team also developed a potential strategy for suppressing inflammation within atherosclerotic plaques, the first approach that targets the immune system's contribution to cardiovascular disease. Their work in animal models of heart disease is described in a Science Translational Medicine paper.

"We found that activation of sympathetic nerve fibers within the arterial lining, which takes place in response to a heart attack, leads to increased expression of adhesion molecules on the endothelial cells lining atherosclerotic plaques. Those molecules both attract inflammatory white blood cells and cause those cells to stick to the plaques, increasing the risk for another heart attack," says Matthias Nahrendorf, MD, PhD, of the MGH Center for Systems Biology, co-senior author of the report. "We also found that we can shut off the expression of those adhesion molecules by means of nanoparticle-delivered RNA interference."

A 2012 Nature study led by Nahrendorf was the first to show that an experimentally induced heart attack led both to the increased generation of monocytes and other inflammatory cells and to the accumulation of those cells in existing atherosclerotic plaques. These immune cells attach themselves to and penetrate within endothelial cells by means of adhesion molecules on the surface of endothelial cells. In the current study, a series of experiments with a mouse model of atherosclerosis revealed that activity of sympathetic nerve fibers within the animals' aortas was responsible for the increased expression of several adhesion molecules after a heart attack.

The investigators then tested whether small interfering RNA (siRNA), which precisely targets the production of specific proteins, could be used to reduce the expression of adhesion molecules on endothelial cells. This was accomplished by means of nanoparticles targeting all five adhesion molecules known to be expressed at sites of arterial inflammation. A 2011 study by Nahrendorf and several members of the current research team - including co-senior author Daniel Anderson, PhD, of MIT - had utilized siRNA nanoparticles to target a single inflammatory receptor protein.

Targeting all five adhesion molecules not only reduced the recruitment of inflammatory immune cells to aortal plaques in the animals, it also lowered the expression of inflammatory proteins called cytokines and enzymes that contribute to the rupture of arterial plaque that triggers a heart attack. Applying the treatment before an induced heart attack reduced subsequent inflammatory changes, while treatment after a heart attack cut the recruitment of inflammatory cells in half and improved the recovery of heart function. A nanoparticle targeting a single adhesion molecule was significantly less effective.

"No current cardiovascular therapy targets the recruitment of immune cells to plaques, although that is the primary contributor to future ischemic events - those caused by a cutoff of blood supply," says Nahrendorf, who is an associate professor of Radiology at Harvard Medical School. "Once this approach is translated, we hope it may help to 'cool down' inflammation in patients with ischemic organ injury, protecting cardiac patients from a second heart attack and helping the heart to recover. We now need to test this approach in larger animals and confirm its safety before it can be tested in human patients."
In addition to co-senior author Daniel Anderson, PhD, of MIT, the co-lead authors of the Science Translational Medicine study are Hendrik Sager, and Partha Dutta, MGH Center for Systems Biology; and James Dahlman, PhD, MIT. Support for the study includes National Institutes of Health grants HL114477, HL117829, HL096576 and K99-HL121076.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals, earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service and returned to the number one spot on the 2015-16 U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.